SHUBHA P SHETTY

Allopathic & Osteopathic Physicians|Family Medicine MISSOURI CITY, TX NPI 1760645295

General Payments — all program years on this page

$2,426.70

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 61
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $843.31 across 18 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $843.3118

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Acerta Pharma LLC $319.797
Amgen Inc. $225.676
Novo Nordisk AS $116.141
Nevro Corp. $98.571
Lilly USA, LLC $65.342
Kowa Pharmaceuticals America, Inc. $17.801

By program year

Program yearAmountRecords
2018 $122.643
2019 $383.126
2020 $307.687
2021 $25.402
2022 $329.9612
2023 $414.5913
2024 $843.3118

Records — PY2024 (18)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1096823155 Novo Nordisk Inc $116.14 08/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104287150 AstraZeneca Pharmaceuticals LP $102.60 06/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104306320 AstraZeneca Pharmaceuticals LP $18.27 02/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104322474 AstraZeneca Pharmaceuticals LP $17.74 02/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104326888 AstraZeneca Pharmaceuticals LP $25.56 07/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105279885 AstraZeneca Pharmaceuticals LP $14.84 10/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105354466 AstraZeneca Pharmaceuticals LP $18.92 05/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105634750 AstraZeneca Pharmaceuticals LP $121.86 05/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1113470529 Kowa Pharmaceuticals America, Inc. $17.80 02/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116118518 Amgen Inc. $124.40 06/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117682856 Amgen Inc. $18.72 01/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117682858 Amgen Inc. $23.74 03/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117682860 Amgen Inc. $17.41 05/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117682862 Amgen Inc. $21.69 06/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117682864 Amgen Inc. $19.71 11/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1130774805 Nevro Corp. $98.57 06/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135393025 Lilly USA, LLC $25.56 08/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135426700 Lilly USA, LLC $39.78 04/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.